Q-omics provides the consensus-scored DPH6 profile across patient tissues and cancer cell-line models. DPH6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DPH6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, DPH6 RNA expression shows 20,245 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where DPH6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPH6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPH6 survival associations across molecular data types. DPH6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPH6 RNA expression–survival associations across cancer types. High DPH6 expression shows unfavorable associations in UVM, PAAD, COAD and BLCA, but favorable associations in MESO and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DPH6 RNA expression.
This table summarizes DPH6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DPH6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPH6 shows lower tumor expression in THCA and UCEC and higher tumor expression in COAD, LIHC, HNSC and BLCA. The THCA box plot shows higher DPH6 RNA expression in normal versus tumor tissue (log2 FC = −0.575, t-test p < 0.001).
This table shows molecular features associated with DPH6 in patient tissues and cancer cell lines. In patient samples, DPH6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPH6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
